Hypera S.A (HYPE3) - Total Assets
Based on the latest financial reports, Hypera S.A (HYPE3) holds total assets worth R$29.50 Billion BRL (≈ $5.79 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Hypera S.A debt service capacity to assess how comfortably operating cash covers total debt obligations.
Hypera S.A - Total Assets Trend (2005–2025)
This chart illustrates how Hypera S.A's total assets have evolved over time, based on quarterly financial data. See HYPE3 book value for net asset value and shareholders' equity analysis.
Hypera S.A - Asset Composition Analysis
Current Asset Composition (December 2025)
Hypera S.A's total assets of R$29.50 Billion consist of 21.2% current assets and 78.9% non-current assets.
| Asset Category | Amount (BRL) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$1.64 Billion | 5.8% |
| Accounts Receivable | R$2.08 Billion | 7.3% |
| Inventory | R$2.08 Billion | 7.3% |
| Property, Plant & Equipment | R$4.23 Billion | 14.8% |
| Intangible Assets | R$4.72 Billion | 16.5% |
| Goodwill | R$7.34 Billion | 25.7% |
Asset Composition Trend (2005–2025)
This chart illustrates how Hypera S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hypera S.A stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hypera S.A's current assets represent 21.2% of total assets in 2025, a decrease from 45.9% in 2005.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2025, up from 0.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, a decrease from 53.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 25.7% of total assets.
Hypera S.A Competitors by Total Assets
Key competitors of Hypera S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥3.12 Billion |
Hypera S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 1.26 | 1.93 |
| Quick Ratio | 1.35 | 0.80 | 1.53 |
| Cash Ratio | 0.00 | 0.36 | 0.69 |
| Working Capital | R$3.28 Billion | R$1.22 Billion | R$2.71 Billion |
Hypera S.A - Advanced Valuation Insights
This section examines the relationship between Hypera S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.03 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 16.4% |
| Total Assets | R$28.59 Billion |
| Market Capitalization | $2.78 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hypera S.A's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hypera S.A's assets grew by 16.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hypera S.A (2005–2025)
The table below shows the annual total assets of Hypera S.A from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | R$28.59 Billion ≈ $5.61 Billion |
+16.43% |
| 2024-12-31 | R$24.56 Billion ≈ $4.82 Billion |
+0.21% |
| 2023-12-31 | R$24.51 Billion ≈ $4.81 Billion |
+3.17% |
| 2022-12-31 | R$23.76 Billion ≈ $4.66 Billion |
+19.87% |
| 2021-12-31 | R$19.82 Billion ≈ $3.89 Billion |
+14.89% |
| 2020-12-31 | R$17.25 Billion ≈ $3.38 Billion |
+44.72% |
| 2019-12-31 | R$11.92 Billion ≈ $2.34 Billion |
+12.91% |
| 2018-12-31 | R$10.56 Billion ≈ $2.07 Billion |
+4.21% |
| 2017-12-31 | R$10.13 Billion ≈ $1.99 Billion |
-11.01% |
| 2016-12-31 | R$11.38 Billion ≈ $2.23 Billion |
-28.06% |
| 2015-12-31 | R$15.82 Billion ≈ $3.10 Billion |
+13.94% |
| 2014-12-31 | R$13.89 Billion ≈ $2.73 Billion |
+11.08% |
| 2013-12-31 | R$12.50 Billion ≈ $2.45 Billion |
-1.22% |
| 2012-12-31 | R$12.66 Billion ≈ $2.48 Billion |
-5.02% |
| 2011-12-31 | R$13.33 Billion ≈ $2.61 Billion |
+33.42% |
| 2010-12-31 | R$9.99 Billion ≈ $1.96 Billion |
+63.89% |
| 2009-12-31 | R$6.09 Billion ≈ $1.20 Billion |
+70.91% |
| 2008-12-31 | R$3.57 Billion ≈ $699.59 Million |
+80.93% |
| 2007-12-31 | R$1.97 Billion ≈ $386.66 Million |
+517.30% |
| 2006-12-31 | R$319.23 Million ≈ $62.64 Million |
+23.92% |
| 2005-12-31 | R$257.60 Million ≈ $50.55 Million |
-- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more